Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ampio Pharmaceuticals Inc AMPE

Healthcare
Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.

Recent & Breaking News (OTCPK:AMPE)

Ampio Updates Regulatory and IP Activities

PR Newswire May 29, 2018

Ampio Provides Corporate Update

PR Newswire May 14, 2018

The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal

PR Newswire May 2, 2018

Ampio Updates Regulatory and Clinical Activities

PR Newswire April 3, 2018

Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections

PR Newswire March 26, 2018

Ampio Pharmaceuticals Provides Corporate Update Following Conference Call

PR Newswire March 15, 2018

Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST

PR Newswire March 6, 2018

Biotech Stocks' Research Reports Released on Ampio Pharma, AmpliPhi Biosciences, Actinium Pharma, and BioPharmX

PR Newswire January 25, 2018

Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions

PR Newswire January 16, 2018

Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders

PR Newswire January 8, 2018

Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

PR Newswire December 14, 2017

Ampio Pharmaceuticals Announces Engagement of LaVoieHealthScience for Integrated Public and Investor Relations

PR Newswire November 30, 2017

Ampio Announces Publication of Ampion™ Treatment of Severe Osteoarthritis of the Knee as a Feature Article in Orthopedics Peer-Reviewed Journal

PR Newswire November 22, 2017

Ampio Pharmaceuticals, Inc. Announces Continued Listing Plan Accepted by NYSE American

PR Newswire November 16, 2017

Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion™ in Severe Osteoarthritis of the Knee

PR Newswire November 15, 2017

Stock Performance Review on Biotech Industry -- Ampio Pharma, AmpliPhi Biosciences, Actinium Pharma, and BioPharmX

PR Newswire October 27, 2017

Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

PR Newswire October 18, 2017

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

PR Newswire October 16, 2017

Ampio Announces Accepted Publication of Pooled Ampion™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee

PR Newswire October 12, 2017

Stock Performance Review on Biotech Industry -- Intrexon, Ampio Pharma, AmpliPhi Biosciences, and CorMedix

PR Newswire September 19, 2017